Technical Analysis for CTIC - Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 0.7631 0.94% 0.01
CTIC closed up 0.94 percent on Tuesday, October 15, 2019, on 33 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Down
See historical CTIC trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish 0.94%
180 Bearish Setup Bearish Swing Setup 0.94%
Oversold Stochastic Weakness 0.94%
Crossed Above 50 DMA Bullish -1.90%
Hammer Candlestick Bullish -1.90%
Stochastic Buy Signal Bullish -1.90%
Lizard Bullish Bullish Day Trade Setup -1.90%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.90%

Older signals for CTIC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
CTIC Chart by TradingView
Basic chart:
Profile
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Cancer Chemical Compounds Organic Compounds Cancer Treatments Ovarian Cancer Acute Myeloid Leukemia Antibody Drug Conjugates Seattle Genetics Ethers Head And Neck Cancer Pyrrolidines Treatment Of Ovarian Cancer Treatment Of Acute Myeloid Leukemia Camidanlumab Tesirine Myelofibrosis Triple Negative Breast Cancer Pacritinib Pixantrone Treatment Of Head And Neck Cancer
Is CTIC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 1 Dosing underway in CTI Bio's late-stage Pacifica trial
Oct 1 CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia
Aug 1 CTI BioPharma EPS in-line
Aug 1 CTI BioPharma Reports Second Quarter 2019 Financial Results
Jul 18 CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
Jun 13 CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
May 29 CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
May 2 CTI BioPharma: 1Q Earnings Snapshot
May 2 CTI BioPharma beats by $0.02
May 2 CTI BioPharma Reports First Quarter 2019 Financial Results
See more CTIC news...
Indicators
Indicator Value
52 Week High 2.04
52 Week Low 0.6
Average Volume 116,028
200-Day Moving Average 0.9026
50-Day Moving Average 0.761
20-Day Moving Average 0.8184
10-Day Moving Average 0.7696
Average True Range 0.0431
ADX 19.34
+DI 13.7531
-DI 19.0389
Chandelier Exit (Long, 3 ATRs ) 0.7907
Chandelier Exit (Short, 3 ATRs ) 0.8593
Upper Bollinger Band 0.9255
Lower Bollinger Band 0.7113
Percent B (%b) 0.24
BandWidth 26.173021
MACD Line -0.0091
MACD Signal Line 0.0016
MACD Histogram -0.0107
Fundamentals Value
Market Cap 24.21 Million
Num Shares 31.7 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -0.41
Price-to-Sales 2.78
Price-to-Book 2.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.84
Resistance 3 (R3) 0.83 0.81 0.82
Resistance 2 (R2) 0.81 0.79 0.81 0.82
Resistance 1 (R1) 0.78 0.78 0.79 0.79 0.82
Pivot Point 0.76 0.76 0.76 0.76 0.76
Support 1 (S1) 0.74 0.74 0.75 0.74 0.71
Support 2 (S2) 0.71 0.73 0.71 0.71
Support 3 (S3) 0.69 0.71 0.70
Support 4 (S4) 0.69